Cargando…

Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer

BACKGROUND: The one-step nucleic acid amplification (OSNA) assay is a rapid procedure for the detection of lymph node (LN) metastases using molecular biological techniques. The aim of this study was to assess the reliability of the whole sentinel lymph node (SLN) analysis by the OSNA assay as a pred...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohi, Y, Umekita, Y, Sagara, Y, Rai, Y, Yotsumoto, D, Matsukata, A, Baba, S, Tamada, S, Matsuyama, Y, Ando, M, Sasaki, M, Tsuchimochi, S, Tanimoto, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494436/
https://www.ncbi.nlm.nih.gov/pubmed/22929881
http://dx.doi.org/10.1038/bjc.2012.387
_version_ 1782249389694124032
author Ohi, Y
Umekita, Y
Sagara, Y
Rai, Y
Yotsumoto, D
Matsukata, A
Baba, S
Tamada, S
Matsuyama, Y
Ando, M
Sagara, Y
Sasaki, M
Tsuchimochi, S
Tanimoto, A
Sagara, Y
author_facet Ohi, Y
Umekita, Y
Sagara, Y
Rai, Y
Yotsumoto, D
Matsukata, A
Baba, S
Tamada, S
Matsuyama, Y
Ando, M
Sagara, Y
Sasaki, M
Tsuchimochi, S
Tanimoto, A
Sagara, Y
author_sort Ohi, Y
collection PubMed
description BACKGROUND: The one-step nucleic acid amplification (OSNA) assay is a rapid procedure for the detection of lymph node (LN) metastases using molecular biological techniques. The aim of this study was to assess the reliability of the whole sentinel lymph node (SLN) analysis by the OSNA assay as a predictor of non-SLN metastases. METHODS: Consecutive 742 patients with breast cancer were enroled in the study. The association of non-SLN or ⩾4 LN metastases with clinicopathological variables was investigated using multivariate logistic analysis. RESULTS: In total, 130 patients with a positive SLN who underwent complete axillary LN dissection were investigated. The frequency of non-SLN metastases in patients who were OSNA+ and ++ was 19.3% and 53.4%, respectively, and that in patients with ⩾4 LN metastases who were OSNA+ and ++ was 7.0% and 27.4%, respectively. The cytokeratin 19 (CK19) mRNA copy number (⩾5.0 × 10(3); OSNA++) in the SLN was the most significant predictors of non-SLN metastases (P=0.003). The CK19 mRNA copy number (⩾1.0 × 10(5)) in the SLN was the only independent predictor of ⩾4 LN metastases (P=0.014). CONCLUSION: Whole SLN analysis using the OSNA assay could become a valuable method for predicting non-SLN and ⩾4 LN metastases.
format Online
Article
Text
id pubmed-3494436
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34944362013-10-09 Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer Ohi, Y Umekita, Y Sagara, Y Rai, Y Yotsumoto, D Matsukata, A Baba, S Tamada, S Matsuyama, Y Ando, M Sagara, Y Sasaki, M Tsuchimochi, S Tanimoto, A Sagara, Y Br J Cancer Clinical Study BACKGROUND: The one-step nucleic acid amplification (OSNA) assay is a rapid procedure for the detection of lymph node (LN) metastases using molecular biological techniques. The aim of this study was to assess the reliability of the whole sentinel lymph node (SLN) analysis by the OSNA assay as a predictor of non-SLN metastases. METHODS: Consecutive 742 patients with breast cancer were enroled in the study. The association of non-SLN or ⩾4 LN metastases with clinicopathological variables was investigated using multivariate logistic analysis. RESULTS: In total, 130 patients with a positive SLN who underwent complete axillary LN dissection were investigated. The frequency of non-SLN metastases in patients who were OSNA+ and ++ was 19.3% and 53.4%, respectively, and that in patients with ⩾4 LN metastases who were OSNA+ and ++ was 7.0% and 27.4%, respectively. The cytokeratin 19 (CK19) mRNA copy number (⩾5.0 × 10(3); OSNA++) in the SLN was the most significant predictors of non-SLN metastases (P=0.003). The CK19 mRNA copy number (⩾1.0 × 10(5)) in the SLN was the only independent predictor of ⩾4 LN metastases (P=0.014). CONCLUSION: Whole SLN analysis using the OSNA assay could become a valuable method for predicting non-SLN and ⩾4 LN metastases. Nature Publishing Group 2012-10-09 2012-08-28 /pmc/articles/PMC3494436/ /pubmed/22929881 http://dx.doi.org/10.1038/bjc.2012.387 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Ohi, Y
Umekita, Y
Sagara, Y
Rai, Y
Yotsumoto, D
Matsukata, A
Baba, S
Tamada, S
Matsuyama, Y
Ando, M
Sagara, Y
Sasaki, M
Tsuchimochi, S
Tanimoto, A
Sagara, Y
Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer
title Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer
title_full Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer
title_fullStr Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer
title_full_unstemmed Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer
title_short Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer
title_sort whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494436/
https://www.ncbi.nlm.nih.gov/pubmed/22929881
http://dx.doi.org/10.1038/bjc.2012.387
work_keys_str_mv AT ohiy wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT umekitay wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT sagaray wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT raiy wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT yotsumotod wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT matsukataa wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT babas wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT tamadas wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT matsuyamay wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT andom wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT sagaray wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT sasakim wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT tsuchimochis wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT tanimotoa wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer
AT sagaray wholesentinellymphnodeanalysisbyamolecularassaypredictsaxillarynodestatusinbreastcancer